Mon, Dec 22, 2014, 8:50 AM EST - U.S. Markets open in 40 mins.


% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • harshal1981 Jul 31, 2013 12:14 PM Flag

    I still don't get all the rosy share price estimates....


    In right before both the CRLs, we had highest share price of no more than $10. Since then we have had significant dilution. Now understood that confidence level on trial is high but how in their sane mind people are projecting $12 to $20 share prices post the data release and prior to approval ? Mathematically it just doesn't make sense. The market potential has not changed. Diabetic patient pool and the potential of inhaled insulin has not magically changed since last CRLs.

    So if market put the SP at $10 during runup before last CRL, I don't see any reason why this time it should cross any thing beyond $9 prior to approval. Post approval share price can't be more than double ($18) provided they have some licensing deal in place. if they are going solo, it will be no more than $11-$13.

    In conclusion, my logical analysis says that most of the upside is already reflected in the current share price as long as the pre-approval time frame is concerned.

    Not sure on this board any one is thinking in their right mind.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.36+0.05(+0.93%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.